Hepatitis B News and Research

Latest Hepatitis B News and Research

UCB to present new data on Cimzia at ACG annual scientific meeting

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, will present new data on Cimzia at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place in Washington D.C. from October 28 to November 2.

1 Nov 2011

FDA grants Premarket Approval for Roche's IgM antibody to hepatitis B core antigen assay

Roche announced today that the U.S. Food and Drug Administration granted Premarket Approval for its IgM antibody to hepatitis B core antigen (Anti-HBc IgM) assay for use on the cobas e 601 analyzer, the immunoassay module of the cobas 6000 analyzer series for mid-volume laboratories.

From Roche Sequencing and Life Science 31 Oct 2011

Astex to present data on direct acting antiviral agents against HCV at 62nd AASLD meeting

Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics, announced that it will present data on its novel, first-in-class direct acting antiviral agents (DAA) against Hepatitis C Virus (HCV) at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.

31 Oct 2011

Fierce Vaccines highlights Inovio's VGX-3100 as one of 10 Promising Therapeutic Vaccines

Inovio Pharmaceuticals, Inc., which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that VGX-3100, its investigational SynCon vaccine for treating cervical dysplasia and cancer caused by human papillomavirus, was highlighted by Fierce Vaccines as one of 10 Promising Therapeutic Vaccines.

31 Oct 2011

Merck third quarter global sales increase 8% to $12.0 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2011.

29 Oct 2011

Gilead, Bristol-Myers Squibb to develop and commercialize fixed-dose combination for HIV

Bristol-Myers Squibb Company and Gilead Sciences, Inc. today announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb's protease inhibitor REYATAZ (atazanavir sulfate) and Gilead's cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.

27 Oct 2011

Insulin resistance paradox

Obesity and insulin resistance are almost inevitably associated with increases in lipid accumulation in the liver, a serious disease that can deteriorate to hepatitis and liver failure. A real paradox in understanding insulin resistance is figuring out why insulin-resistant livers make more fat. Insulin resistance occurs when the body does a poor job of lowering blood sugars.

27 Oct 2011

Scientists, WHO warn of public health implications of proposed mercury ban due to its use in vaccines

"Scientists are warning officials negotiating a global treaty on mercury that banning the deadly chemical completely would be dangerous for public health because of the chemical's use in vaccines," the Associated Press reports.

24 Oct 2011

Vertex initiates INCIVEK combination Phase 3b study for hepatitis C

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called CONCISE that will evaluate the potential for treatment with INCIVEK (telaprevir) combination therapy to be shortened to 12 weeks in people with genotype 1 chronic hepatitis C who have the 'CC' variation near the IL28B gene.

24 Oct 2011

SafeMinds praises UNEP's draft treaty ban on use of mercury in pharma products

SafeMinds applauds UNEP's draft treaty language which does not exempt the use of mercury in pharmaceutical products, including vaccines, from the global ban. Governmental regulators, public health officials and pharmaceutical companies have recognized that the toxicity of mercury in pharmaceutical and personal care products, to which people are directly exposed, justifies a preventive approach to minimize all exposures.

24 Oct 2011

Sewage provides perfect ecosystem for studying diversity of uncharacterized viral populations

Raw sewage provides a perfect ecosystem for studying the diversity of viral populations that remain uncharacterized. This is one of the principal conclusions of a study published in the journal mBio by a team comprising experts from the UB's Laboratory of Water and Food Viral Pollution, Washington University and the University of Pittsburgh, under the direction of James Pipas.

22 Oct 2011

PATH B programme for patients with hepatitis B launches in Europe

A pioneering educational resource, designed to improve the lives of people living with chronic hepatitis B, was launched today at an annual conference organised by Bristol-Myers Squibb in Hong Kong where 26 patient advocacy groups from 14 countries and regions gathered to discuss viral hepatitis.

22 Oct 2011

Common risk factors for hepatocellular cancer

Among known risk factors for hepatocellular cancer, smoking, obesity, and heavy alcohol consumption, along with chronic hepatitis B and C infection, contribute to a large share of the disease burden in Europe, according to a cohort study published online October 21 in the Journal of the National Cancer Institute.

22 Oct 2011

Boehringer Ingelheim announces new data from hepatitis C virus portfolio

Boehringer Ingelheim announced today that new data from its hepatitis C virus (HCV) portfolio will be presented in scientific sessions at The Liver Meeting 2011, the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 4 - November 8 in San Francisco, CA.

22 Oct 2011

Two Philadelphia scientists to receive John Scott Award

Two internationally recognized scientists with strong Philadelphia ties are to receive the John Scott Award this year.

21 Oct 2011

Acute HCV screening strategy for HIV-infected individuals

Researchers at The Miriam Hospital demonstrated a practical strategy for regularly screening HIV-infected patients for acute hepatitis C virus infection (HCV), a "silent epidemic" that is rising undetected in this population and can lead to serious health complications.

19 Oct 2011

Roundup: Mass. contemplates 'global payments'; rural hospitals struggling; Oregon liability cost studied

Although important details remain to be negotiated, the legislative leaders and Gov. Deval Patrick, all Democrats, are working toward a plan that would encourage flat "global payments" to networks of providers for keeping patients well, replacing the fee-for-service system that creates incentives for excessive care by paying for each visit and procedure.

19 Oct 2011

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson today announced sales of $16.0 billion for the third quarter of 2011, an increase of 6.8% as compared to the third quarter of 2010. Operational results increased 2.6% and the positive impact of currency was 4.2%. Domestic sales declined 3.7%.

18 Oct 2011

Roche to acquire Anadys Pharmaceuticals

Anadys Pharmaceuticals, Inc. today announced that it has entered into a definitive merger agreement to be acquired by Roche.

18 Oct 2011

Molecular switch activates anti-viral innate immune response

When a thief breaks into a bank vault, sensors are activated and the alarm is raised. Cells have their own early-warning system for intruders, and scientists at the European Molecular Biology Laboratory (EMBL) in Grenoble, France, have discovered how a particular protein sounds that alarm when it detects invading viruses.

15 Oct 2011